HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era
Author(s) -
Silvia Montoto,
Kate Shaw,
Jessica Okosun,
Shreyans Gandhi,
Paul Fields,
Andrew Wilson,
Milensu Shanyinde,
Kate Cwynarski,
Robert Marcus,
Johannes de Vos,
Anna Marie P. Young,
M TenantFlowers,
Chloe Orkin,
Margaret A. Johnson,
Daniella Chilton,
John G. Gribben,
Mark Bower
Publication year - 2012
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2011.41.4193
Subject(s) - dacarbazine , medicine , vinblastine , bleomycin , abvd , chemotherapy , doxorubicin , lymphoma , human immunodeficiency virus (hiv) , hodgkin lymphoma , antiretroviral therapy , oncology , surgery , vincristine , virology , cyclophosphamide , viral load
The prognosis of HIV-infected patients with non-Hodgkin lymphoma in the highly active antiretroviral therapy (HAART) era approaches that of the general population when they are treated with the same protocols. We analyzed the outcome of patients with Hodgkin lymphoma (HL) treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in the HAART era according to HIV serostatus to establish whether this also holds true for HL.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom